Biomarkers in maternal blood can identify pregnant women with lupus at low risk for adverse outcomes

Pregnant women with systemic lupus erythematosus, are at higher risk for adverse pregnancy outcomes, including preeclampsia, placental insufficiency, fetal death, miscarriages, and other complications. A consortium of top researchers funded by NIH/NIAMS report that monitoring specific angiogenic biomarkers in maternal blood during early pregnancy can successfully predict patients who will likely have normal pregnancies and those at high risk for adverse outcomes. This will enable physicians to identify, counsel, and manage high risk patients at an early stage of pregnancy. —> Read More